Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 3Uterine Cervical Neoplasms 2Camurati-Engelmann Syndrome 2Triple Negative Breast Neoplasms 1Metastatic Solid Tumors 1Lung Neoplasms 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 27Cisplatin 24pembrolizumab 15durvalumab 12Fluorouracil 11Capecitabine 10Oxaliplatin 9Leucovorin 8Bevacizumab 7Carboplatin 5Paclitaxel 4Nivolumab 4Irinotecan 4Injections 4zanidatamab 3trametinib 3lenvatinib 3derazantinib 3atezolizumab 3Ramucirumab 3Docetaxel 3tremelimumab 2surufatinib 2pertuzumab 2gemcitabine-oxaliplatin regimen 2envafolimab 2Trastuzumab 2S 1 (combination) 2Itraconazole 2Cetuximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Biliary Tract Neoplasms × bintrafusp alfa protein, human × Clear all
NCT03833661 2023-10-25

M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)

EMD Serono

Phase 2 Completed
159 enrolled 23 charts
Gastrointestinal

Biliary Tract Neoplasms, Camurati-Engelmann Syndrome, Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡